Skip to Main Content

Author Details

Sharyn D Baker
Ohio State University
1994
215
61
Andrej Sali (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
38071551Vincristine Disposition and Neurotoxicity Are Unchanged in Humanized CYP3A5 Mice.Drug Metab Dispos2024
36821823<i>DPYD</i> Testing: Time to Put Patient Safety First.J Clin Oncol2023
37603350Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study.Blood Adv2023
37059009Determination and disposition of meta-iodobenzylguanidine in plasma and heart of transporter-deficient mice by UPLC-MS/MS.J Chromatogr B Analyt Technol Biomed Life Sci2023
37347545Targeting a xenobiotic transporter to ameliorate vincristine-induced sensory neuropathy.JCI Insight2023
37286564Author Correction: Increased renal elimination of endogenous and synthetic pyrimidine nucleosides in concentrative nucleoside transporter 1 deficient mice.Nat Commun2023
37345219DNA methyltransferase inhibitor exposure-response: Challenges and opportunities.Clin Transl Sci2023
37398194Proposal of a new genomic framework for categorization of pediatric acute myeloid leukemia associated with prognosis.Res Sq2023
34117715Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions.Basic Clin Pharmacol Toxicol2022
35797240BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors.Blood Adv2022
35608822Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study.Clin Cancer Res2022
35344039Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication.Clin Cancer Res2022
35456528Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination.Pharmaceutics2022
36612026TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with <i>TP53</i> Mutation/Deletion.Cancers (Basel)2022
36145680A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug-Drug Interaction Liabilities.Pharmaceutics2022
36296409Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B.Molecules2022
36054985Determination of the endogenous OATP1B biomarkers glycochenodeoxycholate-3-sulfate and chenodeoxycholate-24-glucuronide in human and mouse plasma by a validated UHPLC-MS/MS method.J Chromatogr B Analyt Technol Biomed Life Sci2022
35083502The effects of pazopanib on doxorubicin pharmacokinetics in children and adults with non-rhabdomyosarcoma soft tissue sarcoma: a report from Children's Oncology Group and NRG Oncology study ARST1321.Cancer Chemother Pharmacol2022
32905646DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia.Clin Transl Sci2021
33495337Targeting OCT3 attenuates doxorubicin-induced cardiac injury.Proc Natl Acad Sci U S A2021
34950932Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition.Cancer Res Commun2021
34614509Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in acute myeloid leukemia.Blood Adv2021
34518298Gilteritinib Inhibits Glutamine Uptake and Utilization in <i>FLT3</i>-ITD-Positive AML.Mol Cancer Ther2021
34778799Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators.Blood Cancer Discov2021
34534550Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition.Kidney Int2021
34365291Development, validation, and application of an LC-MS/MS method for the determination of the AXL/FLT3 inhibitor gilteritinib in mouse plasma.J Chromatogr B Analyt Technol Biomed Life Sci2021
31102119Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.Invest New Drugs2020
31645648A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia.Leukemia2020
31992353Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia.J Hematol Oncol2020
33268594TP-0903 is active in models of drug-resistant acute myeloid leukemia.JCI Insight2020
32916864Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors.Pharmaceutics2020
32825359Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib.Pharmaceutics2020
32114507Role of Oatp2b1 in Drug Absorption and Drug-Drug Interactions.Drug Metab Dispos2020
32300185Correction: A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia.Leukemia2020
32534260Development and validation of a sensitive UHPLC-MS/MS analytical method for venetoclax in mouse plasma, and its application to pharmacokinetic studies.J Chromatogr B Analyt Technol Biomed Life Sci2020
32317630A kinome-wide screen identifies a CDKL5-SOX9 regulatory axis in epithelial cell death and kidney injury.Nat Commun2020
31350763Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1.Clin Pharmacol Ther2020
30651561Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.Nat Commun2019
31832201Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice.Pharmacol Res Perspect2019
31350825Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3-ITD AML.Clin Transl Sci2019
31455680Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies.Clin Cancer Res2019
30955241Interaction Between Sex and Organic Anion-Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib-N-Oxide and Regorafenib-Glucuronide in Mice.Clin Transl Sci2019
29227282Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia.J Clin Invest2018
30899769Hypoxia Reporter Element Assay.Bio Protoc2018
29783173Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma.J Chromatogr B Analyt Technol Biomed Life Sci2018
27248844Transcriptome profiling of patient derived xenograft models established from pediatric acute myeloid leukemia patients confirm maintenance of FLT3-ITD mutation.Leuk Lymphoma2017
28409853A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03).Pediatr Blood Cancer2017
28493546Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine.Cancer2017
28371445Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide.Clin Transl Sci2017
28209616OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues.Cancer Res2017
  • 1 - 50 of 215

Recommended Authors

Xun Bao
Wayne State University School of Medicine, Barbara Ann Karmanos Cancer Institute
Career Start Year 2014
Number of shared co-authors 1
Marzia Del Re
University of Pisa
Career Start Year 2010
Number of shared co-authors 2
Hong Xie
Janssen Research & Development LLC
Career Start Year 2009
Number of shared co-authors 1
Rajendar K Mittapalli
Pfizer Inc.
Career Start Year 2008
Number of shared co-authors 1
John F Reilly
Goldfinch Bio Inc.
Career Start Year 2007
Number of shared co-authors 4
Ahmed Aman
Ontario Institute for Cancer Research, University Avenue
Career Start Year 2007
Number of shared co-authors 1
Kari M Morrissey
Amunix Pharmaceuticals
Career Start Year 2006
Number of shared co-authors 1
Jordi Rodon
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 10
Shubham Pant
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 5
Allyson J Ocean
Weill Cornell Medical College
Career Start Year 2004
Number of shared co-authors 2
Neeltje Steeghs
Netherlands Cancer Institute-Antoni Van Leeuwenhoek
Career Start Year 2003
Number of shared co-authors 5
Antje-Christine Walz
Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd.
Career Start Year 2002
Number of shared co-authors 0
Mar??a Jos?? Guill??n
Instituto de Investigaciones Biomedicas "Alberto Sols"
Career Start Year 2001
Number of shared co-authors 0
Cristina Rodr??guez-Antona
Spanish National Cancer Research Center (CNIO)
Career Start Year 2000
Number of shared co-authors 2
Salvador Fudio
Clinical Development
Career Start Year 1998
Number of shared co-authors 1
Sunil Sharma
Brody School of Medicine, East Carolina University
Career Start Year 1997
Number of shared co-authors 5
Primo N Lara
University of California Davis Comprehensive Cancer Center
Career Start Year 1996
Number of shared co-authors 7
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 5
Cynthia Sung
Health Services and Systems Research, Duke-NUS Medical School
Career Start Year 1990
Number of shared co-authors 1
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 5
Pablo Avil??s
Departamento de Toxicologia y Farmacologia Preclinica
Career Start Year 1989
Number of shared co-authors 1
Chris Twelves
Leeds Teaching Hospitals NHS Trust, University of Leeds
Career Start Year 1986
Number of shared co-authors 4
Scott J Weir
University of Kansas Medical Center
Career Start Year 1985
Number of shared co-authors 19
David C Smith
Rogel Comprehensive Cancer Center, University of Michigan ann arbor
Career Start Year 1985
Number of shared co-authors 13
Mark J Ratain
University of Chicago
Career Start Year 1985
Number of shared co-authors 20
Lawrence J Lesko
Department of Pharmaceutics, University of Florida
Career Start Year 1979
Number of shared co-authors 10
Anne Monks
Institute of Biomedical Engineering (IBME), University of Oxford
Career Start Year 1976
Number of shared co-authors 2
Paul Workman
The Institute of Cancer Research
Career Start Year 1974
Number of shared co-authors 5
James H Doroshow
National Cancer Institute, National Institutes of Health
Career Start Year 1974
Number of shared co-authors 10
Peter J Houghton
The University of Texas Health Science Center at San Antonio
Career Start Year 1971
Number of shared co-authors 19

Collaborators

Alex Sparreboom
Ohio State University
Co-authored papers 78
Shuiying Hu
The Ohio State University
Co-authored papers 37
Michael A Carducci
Johns Hopkins School of Medicine
Co-authored papers 23
Alice A Gibson
The Ohio State University
Co-authored papers 21
Lie Li
Sino-French Hoffmann Institute, Guangzhou Medical University
Co-authored papers 19
Stanley Pounds
St. Jude Children's Research Hospital.
Co-authored papers 16
Daelynn R Buelow
The Ohio State University
Co-authored papers 15
Antonio C Wolff
Co-authored papers 13
Wells A Messersmith
University of Colorado Anschutz Medical Campus
Co-authored papers 13
Daniel D Von Hoff
Co-authored papers 9
Navjotsingh Pabla
The Ohio State University
Co-authored papers 8
Ching-Hon Pui
St. Jude Children's Research Hospital
Co-authored papers 7
Antonio Jimeno
University of Colorado School of Medicine
Co-authored papers 7
Aksana Vasilyeva
St Jude Children's Research Hospital
Co-authored papers 7
Anne T Nies
and University of Tuebingen, University of Tuebingen
Co-authored papers 5
Elizabeth Garrett-Mayer
Center for Research and Analytics, American Society of Clinical Oncology
Co-authored papers 5
Guoqing Du
Second Affiliated Hospital of Harbin Medical University
Co-authored papers 5
Jeffery M Klco
St. Jude Children's Research Hospital
Co-authored papers 5
Taosheng Chen
St. Jude Children's Research Hospital
Co-authored papers 5
John G Kuhn
Co-authored papers 5
Charles G Mullighan
St Jude Children's Research Hospital
Co-authored papers 4
Matthias Schwab
and of Biochemistry and Pharmacy, University of Tuebingen
Co-authored papers 4
William E Evans
Departments of Oncology. St. Jude Children's Research Hospital
Co-authored papers 4
Lillian L Siu
Princess Margaret Cancer Centre, University Ave
Co-authored papers 4
Xueyuan Cao
University of Chinese Academy of Sciences
Co-authored papers 4
Su Sien Ong
St. Jude Children's Research Hospital
Co-authored papers 3
Robert B Diasio
Mayo Clinic
Co-authored papers 3
Jinghui Zhang
Changhai Hospital, Second Military Medical University
Co-authored papers 3
Jan H M Schellens
Department of Pharmaceutical Sciences, Utrecht University
Co-authored papers 3
Roxann G Ingersoll
Mc-Kusick-Nathans Institute of Genetic Medicine, Johns Hopkins
Co-authored papers 3
Release 1.2